Currently out of the existing stock ratings of Chad Messer, 2 are a HOLD (1.27%), 154 are a BUY (98.09%), 1 are a SELL (0.64%).

Chad Messer

Work Performance Price Targets & Ratings Chart

Analyst Chad Messer, carries an average stock price target met ratio of 48.28% that have a potential upside of 52.71% achieved within 273 days. Previously, Chad Messer worked at NEEDHAM.

Chad Messer’s has documented 284 price targets and ratings displayed on 26 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on BOLT, Bolt Biotherapeutics at 14-Aug-2025.

Wall Street Analyst Chad Messer

Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $47 was fulfilled within 5 days with a profit of $14.55 (44.84%) receiving and performance score of 89.68.

Average potential price target upside

of $52.46 (70.13%) on NXTC (NEXTCURE ).
of $30.96 (81.77%) on SRPT (SAREPTA THERAPEUTICS).
of $22.43 (22.2%) on SGEN (SEAGEN).

AGIO Agios Pharm AKBA Akebia Ther ARQL ArQule CYTK Cytokinetics ESPR Esperion Therapeutics EXEL Exelixis GNCA Genocea Biosciences IONS Ionis Pharmaceuticals PGNX Progenics Pharmaceuticals PHAS PhaseBio Pharmaceuticals SGEN Seagen SRPT Sarepta Therapeutics VCEL Vericel Corp Ord CRMD CorMedix GTHX G1 Therapeutics MREO Mereo BioPharma Group PLC ADR AGLE Aeglea Bio Therapeutics ATHX Athersys AUTL Autolus Therapeutics Ltd SELB Selecta Biosciences GMDA Gamida Cell Ltd NXTC NextCure SMMT Summit Therapeutics PLC ATNX Athenex BOLT Bolt Biotherapeutics CTIC CTi Biopharma Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Emily Bodnar (HC WAINWRIGHT)